Anti-allergy vaccine based on 'hygiene hypothesis'
...d by a Swiss-based Cytos Biotechnology company to develop an anti-allergy drug that makes the immune system to focus on mycobacteria. This drug called cyt003 – QbG10 activates the immune system to attack potentially larger threats like mycobacteria, a group of bacteria found in soil and water that are come ...PipelineReview.com - Biotech News & Online Store - Cytos Biotechnology ...
... Industry, Cytos Biotechnology starts phase IIb clinical study with CYT003-QbG10 ... CYT003- QbG10 has previously been demonstrated to be safe, very ...CYT003-QbG10 Monotherapy For The Treatment Of Allergic Diseases Is Safe ...
Cytos Biotechnology Ltd (SWX:CYTN) announced results from two randomized, double-blind, placebo-controlled, multicentre phase II studies with CYT003-QbG10 ...Start Of Phase IIb Clinical Study With CYT003-QbG10 Monotherapy For The ...
Cytos Biotechnology Ltd (SIX:CYTN) announced today that it has started a phase IIb clinical study with CYT003-QbG10, an allergen-independent immunotherapeutic ...Cytos Biotechnology - Preventing Chronic Diseases – a Vital Investment
Conference Call / Webcast about CYT003-QbG10 phase IIb results. Archived ... CYT003-QbG10 monotherapy for the treatment of allergic rhinoconjunctivitis is ...Universal allergy treatment going to Phase III clinical trials
Cytos Biotechnology has a product CYT003-QbG10 with the potential to treat many ... Study 08 with CYT003-QbG10 monotherapy included 80 patients suffering from house ...A Study to Investigate an Immunomodulatory Therapy in Adult Patients ...
... extract in combination with CYT003-QbG10-placebo. Phase II ... Drug: CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10) ...